trending Market Intelligence /marketintelligence/en/news-insights/trending/cnz1jyte6gurxziyqvtvha2 content esgSubNav
In This List

Pfizer's Xeljanz wins US FDA panel backing as bowel disease treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pfizer's Xeljanz wins US FDA panel backing as bowel disease treatment

A U.S. Food and Drug Administration advisory panel recommended the approval of Pfizer Inc.'s Xeljanz to treat a chronic bowel disease, Reuters reported.

The panel, which consisted of 15 members, unanimously voted in a favor of the drug to treat patients with moderate to severe ulcerative colitis, an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract.

The FDA is not required to act on the advice of its advisory panels but generally does so.

Xeljanz is already approved to treat rheumatoid arthritis and psoriatic arthritis.